The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Ohio Attorney General Dave Yost sent letters to 14 medical spas warning them to stop making false or misleading claims about ...

Whether it's drawing blood or administering medication, needles scare many people, and not everyone can imagine doing it ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1 study in obese or overweight individuals; top-line ...

Q1 2025 Earnings Call Transcript May 13, 2025Fractyl Health, Inc. Common Stock reports earnings inline with expectations.

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug ...

The strategy of rewiring the brain's stress response is rooted in two pieces of scientific literature. One is biochemical.